Indie Asset Partners, LLC Adc Therapeutics Sa Transaction History

Indie Asset Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$0.72 - $2.37 $820 - $2,699	-1,139 Reduced 1.21%	92,700 $83,000
Q3 2022 Oct 25, 2022	SELL	$4.66 - $10.31 $699 - $1,546	-150 Reduced 0.16%	93,839 $452,000
Q2 2022 Aug 12, 2022	SELL	$5.96 - $14.99 $15,394 - $38,719	-2,583 Reduced 2.67%	93,989 $747,000
Q1 2022 May 10, 2022	SELL	$13.28 - $20.03 $132 - $200	-10 Reduced 0.01%	96,572 $1.42 Million
Q4 2021 Feb 11, 2022	SELL	$19.29 - $31.51 $15,991 - $26,121	-829 Reduced 0.85%	96,582 $1.95 Million
Q3 2021 Nov 09, 2021	BUY	$20.45 - $30.0 $117,996 - $173,100	5,770 Added 6.3%	97,411 $2.65 Million
Q2 2021 Aug 11, 2021	SELL	$20.38 - $27.04 $9,680 - $12,844	-475 Reduced 0.52%	91,641 $2.23 Million
Q1 2021 May 13, 2021	SELL	$22.75 - $34.05 $3,890 - $5,822	-171 Reduced 0.19%	92,116 $2.25 Million
Q4 2020 Feb 09, 2021	BUY	$25.26 - $38.02 $2.33 Million - $3.51 Million	92,287 New	92,287 $2.95 Million

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $135M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Indie Asset Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Indie Asset Partners, LLC with notifications on news.